Efficacy of Add-on Amantadine to clonidine on severity of opioid withdrawal symptoms.

Evaluation the efficacy of Add-on Amantadine to clonidine on severity of opioid withdrawal symptoms.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090801002266N15

Enrollment

Registered

2021-05-06

Start date

2021-05-22

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severity of opioids withdrawal symptoms. Opioid dependence, uncomplicated

Interventions

Intervention 1: Intervention group: Clonidine + Amantadine, clonidine made with "drug manufacturing company" in Iran in 0.2 mg tablets and amantadine capsules made in Iran in Hakim Pharmaceutical Co

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Satisfaction to participate in the study Having DSM-V criteria for drug dependence Regular and daily consumption of opium and heroin orally, injected or smoked

Exclusion criteria

Exclusion criteria: The patient's unwillingness to continue cooperation Occurrence of any medical or moral conflict with the continued presence of the patient in the study Occurrence of physical and mental problems requires special interventions in the management of opioid withdrawal

Design outcomes

Primary

Measure	Time frame
The effects of amantadine in controlling of opioids withdrawal symptoms. Timepoint: The severity of withdrawal symptoms (initial outcome) on the first day (24 hours after the last dose of the drug) as a baseline assessment and then on days 3, 7, 14 and 21. Method of measurement: SOWS scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGholam Reza Kheirabadi

Esfahan University of Medical Sciences

kheirabadi@bsrc.mui.ac.ir+98 31 1222 2135

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026